Validose appoints CEO as it prepares launch of multi-therapeutic platform focused on improving clinical trial adherence.

Brooklyn, NY – October 16th, 2024 – Validose, a leading innovator in patient-centric dosing solutions and real-time clinical data integration, has announced the appointment of Paul McGrath as Chief Executive Officer. This leadership change follows an extensive national search to position the company for its next phase of growth as it prepares to launch a multi-therapeutic platform aimed at enhancing clinical trial adherence.

McGrath brings over 20 years of experience driving innovation and scaling global brands across life sciences and healthcare. His background includes pivotal leadership roles at GSK and Pfizer, where he spearheaded organizational transformation, global marketing, and product innovation initiatives. In his new role, McGrath will focus on advancing Validose’s revolutionary dosing technology to market while laying the operational groundwork for future growth.

“We are thrilled to welcome Paul as CEO,” said Marcel Botha, Chairman of the Board at 10XBeta, Validose’s parent company. “His proven track record driving growth and creating lasting value across industries makes him the ideal leader for the commercial launch of Validose. His blend of healthcare expertise and forward-thinking leadership perfectly aligns with our vision to transform clinical trial adherence.”

McGrath added, “I’m excited to join Validose at this pivotal moment.

“The integration of digital health technologies with life sciences presents an extraordinary opportunity to improve patient outcomes and streamline clinical processes. I look forward to working with the board and the team to bring Validose’s unique adherence platform to market, empowering patients and enabling faster, data-driven decisions for our customers.”

- Paul McGrath, CEO, Validose

As CEO, McGrath will oversee the company’s strategic direction, operations, and fundraising efforts. His immediate priority will be leading the launch of Validose’s multi-therapeutic platform designed to address non-adherence in clinical trials, and ultimately enhancing patient experience and trial success.

—

About Validose:

Validose is a health technology pioneer focused on improving medication adherence in clinical trials through advanced dose delivery and monitoring solutions. Our technology enables real-time patient support and clinician oversight, transforming the clinical trial experience by ensuring more reliable data and better outcomes.

For more information, visit validose.com and follow us on LinkedIn.

Contact:

Validose at info@validose.com

63 Flushing Ave, Building 303, Suite 809, Brooklyn, NY 11205